Crohn's T2397M‐mutant LRRK2 patients have reportedly lower levels of LRRK2 protein activity within their immune cells 162, suggesting that one harmful side effect of a complete inhibition of LRRK2 as a treatment for PD could be the development of intestinal‐immune diseases. The gene discussed is LRRK2; the disease is immune system disorder.